A proposed in vitro cytotoxicity test battery to detect and predict hepatotoxicity via multiple mechanisms and pathways: a minireview.
Clone 9 cells
HepG2
HepaRG
assay kit
cytotoxicity
hepatotoxicity
in vitro screening
liver
liver toxicity
toxicity screening
Journal
Journal of applied toxicology : JAT
ISSN: 1099-1263
Titre abrégé: J Appl Toxicol
Pays: England
ID NLM: 8109495
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
revised:
05
04
2024
received:
26
03
2024
accepted:
16
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
The 21st-century toxicity testing program recommends the use of cytotoxicity data from human cells in culture for rapid in vitro screening focusing on biological pathways of potential toxicants to predict in vivo toxicity. Liver is the major organ for both endogenous and exogenous chemical metabolism of xenobiotics. Therefore, this review was undertaken to evaluate side by side five different currently used commercial cytotoxicity assay kits for purpose of rapid predictive screening of potential hepatotoxicants. The test compounds for this review were selected from the NIH LiverTox and FDA Liver Toxicity Knowledge Base (LTKB) databases. Human liver HepG2, HepaRG, and rat liver Clone 9 cell cultures were used as the in vitro liver models. Five commercial assay kits representing different biomarkers or pathways were selected for this review. These kits are Vita-Orange Cell Viability Assay Kit (Sigma-Aldrich), CellTiter-Glo Cell Viability Assay Kit (Promega), CytoTox-ONE Homogeneous Membrane Integrity Assay Kit (Promega), DNA Quantitation Fluorescence Assay Kit (Sigma-Aldrich), and Neutral Red Based In Vitro Toxicology Assay Kit (Sigma-Aldrich). This review found that these kits can all be used for rapid predictive cytotoxicity screening of potential hepatotoxicants in human liver HepG2 and rat liver Clone 9 cells in culture as in vitro liver models without compromising quality and accuracy of endpoint measurements as well as the length of toxicity screening time. Unraveling the structure-activity relationship of potential hepatotoxins would help to classify their hepatotoxic effects. Therefore, in addition to the current regulatory hepatotoxicity testing strategies, development and regulatory approval of hepatotoxins need to be discussed in order to identify potential gaps in the safety assessment. The overall results of our study support the hypothesis that a battery of rapid, simple, and reliable assays is an excellent tool for predicting in vivo effects of suspected liver toxins. The human liver HepaRG cells do not appear to be an ideal in vitro liver model for this purpose.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Auld, D. S., Zhang, Y. Q., Southall, N. T., Rai, G., Landsman, M., MacLure, J., Langevin, D., Thomas, C. J., Austin, C. P., & Inglese, J. (2009). A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. Journal of Medicinal Chemistry, 52, 1450–1458.
Björnsson, E. S. (2016). Hepatotoxicity by drugs: The most common implicated agents. International Journal of Molecular Science, 17(2), 224–231.
Björnsson, E. S., & Hoofnagle, J. H. (2015). Categorization of drugs implicated in causing liver injury: Critical assessment based upon published case reports. Hepatology, 63(2), 590–603.
Burley, T. A., Mączyńska, J., & Shah, A. (2018). Near‐infrared photoimmunotherapy targeting EGFR‐shedding new light on glioblastoma treatment. International Journal of Cancer, 142(11), 2363–2374.
Chow, L. W., Wang, L., Kaufman, D. B., & Stupp, S. I. (2010). Self‐assembling nanostructures to deliver angiogenic factors to pancreatic islets. Biomaterials, 31(24), 6154–6161.
Dambach, D. M., Andrews, B. A., & Moulin, F. (2005). New technologies and screening strategies for hepatotoxicity: Use of in vitro models. Toxicologic Pathology, 33, 17–26.
FDA (U.S. Food and Drug Administration). (2013). Liver toxicity knowledge base. http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/default.htm
Goliwas, K. F., Richter, J. R., Pruitt, H. C., Araysi, L. M., Anderson, N. R., Samant, R. S., Lobo‐Rupert, S. M., Berry, R. L., & Frost, A. R. (2017). Methods to evaluate cell growth, viability and response to treatment in a tissue engineered breast cancer model. Nature Science Reports, 7, 14167.
ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods). (2001). Guidance document on using in vitro data to estimate in vivo starting doses for acute toxicity. NIH Publication No. 014500. Research Triangle Park, NC: National Institute for Environmental Health Sciences. http://iccvam.niehs.nih.gov/methods/acutetox/inv_cyto_guide,htm
Ingawale, D. K., Mandlik, S. K., & Naik, S. R. (2014). Models of hepatoxicity and the underlying cellular, biochemical and immunological mechanisms: A critical discussion. Environmental Toxicology and Pharmacology, 37, 118–133.
Jennen, D. G. J., Magkoufopoulou, C., Ketelslegers, H. B., van Herwijnen, M. H. M., Kleinjans, J. C. S., & van Delft, J. H. M. (2010). Comparison of HepG2 and HepaRG by whole‐genome gene expression analysis for the purpose of chemical hazard identification. Toxicological Science, 115(1), 66–79.
Judson, R., Houck, K., Martin, M., Richard, A. M., Knudsen, T. B., Shah, I., Little, S., Wambaugh, J., Setzer, R. W., Kothya, P., Phuong, J., File, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer, N., Sipes, N., Xia, M., Huang, R., … Thomas, R. S. (2016). Analysis of the effects of cell stress and cytotoxicity on in vitro assay activity across a diverse chemical and assay space. Toxicological Science, 152(2), 323–339.
Judson, R., Kavlock, R., Martin, M., Reif, D., Houck, K., Knudsen, T., Richard, A., Tice, R. R., Whelan, M., Xia, M., Huang, R., Austin, C., Daston, G., Hartung, T., Fowle, J. R., Wooge, W., Tong, W., & Dix, D. (2013). Perspectives on validation of high‐throughput assays supporting 21st century toxicity testing. Altex, 30(1), 51–56.
Mirahmad, M., Sabourian, R., Mahdavi, M., Larijani, B., & Safavi, M. (2022). In vitro cell based models of drug induced hepatotoxicity: Progress and limitations. Drug Metabolism Reviews, 54(2), 161–193.
National Institutes of Health (NIH) (gov). (2023). LiverTox: A website on drug induced liver injury. https://www.niddk.nih.gov
Niles, A. L., Moravec, R. A., & Riss, T. L. (2009). In vitro viability & cytotoxicity testing & same‐well multi‐parametric combinations for high throughput screening. Current Chemistry and Genomics, 3, 33–41. https://doi.org/10.2174/1875397300903010033
NRC (National Research Council). (2007). Toxicity testing in the 21st century: A vision and strategy. National Academy Press.
OECD (Organization for Economic Co‐operation and Development). (2010). Guidance document on using cytotoxicity tests to estimate starting doses for acute oral systemic toxicity tests, no 129 920 July 2010.
Puttonen, K. A., Lehtonen, S., Lampela, P., Männistö, P. T., & Raasmaja, A. (2008). Different viabilities and toxicity types after 6‐OHDA and Ara‐C exposure evaluated by four assays in five cell lines. Toxicology in Vitro, 22(1), 182–189.
Quintas, G., Castell, J. V., & Moreno‐Torres, M. (2023). The assessment of hepatoxicity of new drugs by in vitro metabolomics. Frontiers in Pharmacology, 14, 1155271.
Repetto, G., del Peso, A., & Zurita, J. L. (2008). Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nature Protocols, 3, 1125–1131.
Riss, T., Niles, A., Moravec, M., Karassina, N., & Vidugiriene, J. (2004). Cytotoxicity assays: In vitro methods to measure dead cells. In S. Markossian, A. Grossman, K. Brimacombe, et al. (Eds.), Assay guidance manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences.
Romano, M. R., Gatto, C., & Giurgola, L. (2021). Toxicity threshold of perfluorocarbon liquids for intraocular use: Dose‐response assessment of in vitro cytotoxicity of possible contaminants. Translational Vision Science Technology, 10(7), 16.
Ruela‐de‐Sousa, R. R., Fuhler, G. M., Blom, N., Ferreira, C. V., Aoyama, H., & Peppelenbosch, M. P. (2010). Cytotoxicity of apigenin on leukemia cell lines: Implications for prevention and therapy. Cell Death and Disease, 1, e19.
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013). In vitro models for liver toxicity testing. Toxicology Research, 2(1), 23–39.
Weyermann, J., Lochmann, D., & Zimmer, A. (2005). A practical note on the use of cytotoxicity assays. International Journal of Pharmaceuticals, 288, 369–376.